Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56.1M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
23.2M
-
Shares change
-
-1.33M
-
Total reported value, excl. options
-
$124M
-
Value change
-
-$13M
-
Put/Call ratio
-
3.19
-
Number of buys
-
33
-
Number of sells
-
-51
-
Price
-
$5.33
Significant Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q4 2021
110 filings reported holding BDTX - Black Diamond Therapeutics, Inc. - Common Stock as of Q4 2021.
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.2M shares
of 56.1M outstanding shares and own 41.37% of the company stock.
Largest 10 shareholders include Bellevue Group AG (3.46M shares), NEA Management Company, LLC (3.45M shares), RA CAPITAL MANAGEMENT, L.P. (2.59M shares), BlackRock Inc. (2.25M shares), BOXER CAPITAL, LLC (2.01M shares), Artal Group S.A. (1.65M shares), FEDERATED HERMES, INC. (1.04M shares), VANGUARD GROUP INC (1.01M shares), MORGAN STANLEY (774K shares), and GEODE CAPITAL MANAGEMENT, LLC (396K shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.